In clinical trials, two doses of Aflunov showed antibody titers than protection in over 85 percent of vaccinated individuals . Aflunov was also shown to cross-reactive antibodies against many of the H5 strains caused in humans to elicit disease. Additionally, a single vaccination with Aflunov induces (H5N1 high and rapid serological response in subjects 6-8 years previously with two different doses of a vaccine surrogate H5 primed with the same formulation and including the same MF59 adjuvant as Aflunov but with H5N3. – The EU regulatory filing for Aflunov form the basis for further filings in other parts of the world including Asia, where H5N1 has been reported in many countries.
References Galli, G et al. Adjuvanted H5N1 vaccine induces early CD4 T -cell response long-term long-term persistence of protective antibody levels. Proceedings of the National Academy of Sciences, 106 : 3877-3882. Continue reading “In clinical trials.”